Successful completion of Retail Entitlement Offer
Filed with ASX · · 3 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Security Class Suspension from Quotation PARO
- Paradigm to Recommence Trading
- Replacement Entitlement Offer and Placement Prospectus
- PAR Successful Placement and Fully Underwritten ANREO
- Entitlement Offer and Placement Prospectus
Later from Paradigm Biopharmaceuticals
- Security Class Reinstatement to Quotation PARO
- Paradigm Receives $7.36m R&D Tax Incentive Refund
- Primary Endpoint Achieved in Phase 2 MPS VI Trial
- Half Yearly Report and Accounts
- Type D Response Submitted and Received by the US FDA
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals